Trial Profile

Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OTS 167 (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Proof of concept
Sponsors OncoTherapy Science

15 Nov 2021 Status changed from recruiting to discontinued.
06 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
06 Apr 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com